Diagnostic Accuracy of Infection Biomarkers in the Initial Investigation of Patients With Suspected Pneumonia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

411 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-03-01

Study Completion Date

2022-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to investigate the diagnostic and prognostic value of C-reactive protein (CRP), serum procalcitonin (PCT) and soluble urokinase plasminogen activator receptor (suPAR) in the initial investigation of patients acute hospitalized with suspected community-acquired-pneumonia (CAP)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Accuracy of Lung Injury Biomarkers in the Initial Investigation of Patients With Suspected Pneumonia

NCT04686331

Community-acquired Pneumonia

COMPLETED

Biomarker Guided Antibiotic Treatment in Community-Acquired Pneumonia

NCT03146182

Community Acquired Pneumonia

UNKNOWN NA

Procalcitonin as a Marker of Bacterial Pneumonia

NCT00415753

Pneumonia Bronchitis COPD

COMPLETED NA

Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections

NCT02171338

Pneumonia Acute Exacerbation of Chronic Obstructive Airways Disease

UNKNOWN PHASE4

Procalcitonin Versus C-reactive Protein to Guide Therapy in Community Acquired Pneumonia

NCT01018199

Community-acquired Pneumonia

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Target pneumonia treatment should be initiated within a few hours, which is why early and accurate diagnosis is extremely important. Uncertain or delayed diagnosis will often lead to an overconsumption of broad-spectrum antibiotics, which contributes to increased development of resistant bacteria and thus threaten the treatment options of the future. Pneumonia diagnosis is primarily made today on the basis of clinical symptoms and findings in the form of cough, vomiting, chest pain, fever, shortness of breath, supplemented with X-ray of the lungs, relevant blood tests and analysis of expectoration. However, X-ray is an imprecise diagnostic tool. The diagnosis of CAP is challenged by nonspecific symptoms, uncertain diagnostic methods and waiting time for test results up to several days.

Therefore, numerous studies have investigated biomarkers that can possibly support the diagnosis of CAP. C-reactive protein (CRP) and serum procalcitonin (PCT) are biomarkers that may distinguish CAP from other causes of acute respiratory infections. The CRP biomarker has been endorsed as a guide for antibiotic treatment by the National Institute for Health and Care Excellence (NICE) and PCT was suggested by the American Infectious Diseases Society of America. Soluble urokinase plasminogen activator receptor (suPAR) has emerged as a potentially novel biomarker for inflammatory diseases including pneumonia. Several studies have highlighted suPAR as a significant prognostic mortality marker and strongly related to disease severity and worse outcome in a variety of conditions. It is also a promising biological marker in the diagnosis of CAP.

The diagnostic value of the optimal biomarkers for the diagnosis of CAP remains controversial. The investigators hypothesize that serum CRP, PTC and suPAR have an impact on diagnosing, prognosis, and treatment of patients with a verified community-acquired-pneumonia. The objectives of the study are:

* To identify the diagnostic accuracy of CRP, PCT and suPAR in community-acquired pneumonia
* To identify the prognostic value of CRP, PCT and suPAR in relation to adverse events

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pneumonia, Bacterial

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients suspected of community-acquired pneumonia

All patients admitted to the emergency department with suspected community- acquired pneumonia by the attending physician